Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
Javi Sanz/E+ via Getty Images Sage Therapeutics, Inc. (NASDAQ:SAGE) stock remains a hold for now. The reason why I think this stock should be a "hold" rating is because it expects to report results from its phase 2b KINETIC 2 Study, which is …